Skip to main content

Advertisement

SpringerLink
Log in

Standardized uptake value on FDG-PET as a marker for disease activity in patients with non-Hodgkin’s lymphoma: comparison with serum soluble interleukin-2 receptor values

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

We compared standardized uptake values (SUVs) on positron emission tomography with a glucose analog, 2-[F-18] fluoro-2-deoxy-D-glucose (FDG-PET) and serum soluble interleukin-2 receptor (sIL-2R) values in patients with non-Hodgkin’s lymphoma (NHL) in the pre-, mid- (after three or four cycles), and post-treatment periods of chemotherapy (pre, mid, and post, respectively), and we examined whether the SUV was a useful tumor marker for NHL.

Methods

The SUVs on PET and sIL-2R values were retrospectively evaluated based on all the clinical information available in 40 patients (31 in pre, 24 in mid, and 24 in the post periods). Patients in complete remission status were classified as group A and those with active residual disease in the mid and post periods were classified as group B.

Results

In pre, the SUV and sIL-2R values exhibited sensitivity of 100% and 84%, respectively. In mid, the SUV was lower in group A than in group B, while sIL-2R was not different. The SUV yielded better specificity than sIL-2R (88 % vs 25 %, respectively), though the difference was not significant. In mid, the SUV in patients later assigned to group A in post was lower than than the SUV in group B, whereas sIL-2R was not different. In post, the specificity and accuracy of SUV were better than those of sIL-2R (95 vs 47 %, and 96 vs 58 %, respectively). Both the SUV and sIL-2R were lower in group A than in group B.

Conclusion

The SUV on PET was better than the serum sIL-2R as a marker to evaluate the disease status of NHL, and was considered to be a useful tumor marker for NHL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Peterson BA (1999) Current treatment of follicular low-grade lymphomas. Semin Oncol 26:2–11

    PubMed  CAS  Google Scholar 

  2. Coiffier B (1999) Treatment of aggressive non-Hodgkin’s lymphoma. Semin Oncol 26:12–20

    PubMed  CAS  Google Scholar 

  3. Hauke RJ, Armitage JO (2000) Treatment of non-Hodgkin lymphoma. Curr Opin Oncol 12:412–418

    Article  PubMed  CAS  Google Scholar 

  4. Kaminski MS, Estes J, Zasadny KR, et al. (2000) Radioimmunotherapy with iodine (131) I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 96:1259–1266

    PubMed  CAS  Google Scholar 

  5. Pizzolo G, Chilosi M, Semenzato G (1987) The soluble interleukin-2 receptor in haematological disorders. Br J Haematol 67:377–380

    Article  PubMed  CAS  Google Scholar 

  6. Rubin LA, Nelson DL (1990) The soluble interleukin-2 receptor: biology, function, and clinical application. Ann Intern Med 113: 619–627

    PubMed  CAS  Google Scholar 

  7. Zerler B (1991) The soluble interleukin-2 receptor as a marker for human neoplasia and immune status. Cancer Cells 3:471–479

    PubMed  CAS  Google Scholar 

  8. Chilosi M, Semenzato G, Vinante F, et al. (1989) Increased levels of soluble interleukin-2 receptor in non-Hodgkin’s lymphomas. Relationship with clinical, histologic, and phenotypic features. Am J Clin Pathol 92:186–191

    PubMed  CAS  Google Scholar 

  9. Barak V, Ginzburg M, Kalickman I, et al. (1992) Serum soluble interleukin-2 receptor levels are associated with clinical disease status and histopathological grade in non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. Leuk Lymphoma 7:431–438

    Article  PubMed  CAS  Google Scholar 

  10. Motokura T, Kobayashi Y, Fujita A, et al. (1995) Clinical significance of serial measurement of the serum levels of soluble interleukin-2 receptor and soluble CD8 in malignant lymphoma. Leuk Lymphoma 16:355–362

    Article  PubMed  CAS  Google Scholar 

  11. Wagner DK, Kiwanuka J, Edwards BK, et al. (1987) Soluble interleukin-2 receptor levels in patients with undifferentiated and lymphoblastic lymphomas: correlation with survival. J Clin Oncol 5:1262–1274

    PubMed  CAS  Google Scholar 

  12. Pui CH, Ip SH, Kung P, et al. (1987) High serum interleukin-2 receptor levels are related to advanced disease and a poor outcome in childhood non-Hodgkin’s lymphoma. Blood 70:624–628

    PubMed  CAS  Google Scholar 

  13. Stasi R, Zinzani L, Galieni P, et al. (1994) Detection of soluble interleukin-2 receptor and interleukin-10 in the serum of patients with aggressive non-Hodgkin’s lymphoma. Identification of a subset at high risk of treatment failure. Cancer 74:1792–1800

    Article  PubMed  CAS  Google Scholar 

  14. Kono N, Kanda Y, Yamamoto R, et al. (2000) Prognostic significance of serum soluble interleukin-2 receptor level in non-Hodgkin’s lymphoma: a single center study in Japan. Leuk Lymphoma 37:151–156

    PubMed  CAS  Google Scholar 

  15. Delbeke D (1999) Oncological applications of FDG PET imaging: brain tumors, colorectal cancer, lymphoma and melanoma. J Nucl Med 40:591–603

    PubMed  CAS  Google Scholar 

  16. Delbeke D (1999) Oncological applications of FDG PET imaging. J Nucl Med 40:1706–1715

    PubMed  CAS  Google Scholar 

  17. Gambhir SS, Czernin J, Schwimmer J, et al. (2001) A tabulated summary of the FDG PET literature. J Nucl Med 42:1S–93S

    PubMed  CAS  Google Scholar 

  18. Hoh CK, Glaspy J, Rosen P, et al. (1997) Whole-body FDG-PET imaging for staging of Hodgkin’s disease and lymphoma. J Nucl Med 38:343–348

    PubMed  CAS  Google Scholar 

  19. Moog F, Bangerter M, Diederichs CG, et al. (1997) Lymphoma: role of whole-body 2-deoxy-2-[F-18] fluoro-D-glucose (FDG) PET in nodal staging. Radiology 203:795–800

    PubMed  CAS  Google Scholar 

  20. Romer W, Hanauske AR, Ziegler S, et al. (1998) Positron emission tomography in non-Hodgkin’s lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood 91:4464–4471

    PubMed  CAS  Google Scholar 

  21. Jerusalem G, Beguin Y, Fassotte MF, et al. (1999) Whole-body positron emission tomography using 18F-fluorodeoxyglucose for post-treatment evaluation in Hodgkin’s disease and non-Hodgkin’s lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 94:429–433

    PubMed  CAS  Google Scholar 

  22. Weber WA, Schwaiger M, Avril N (2000) Quantitative assessment of tumor metabolism using FDG-PET imaging. Nucl Med Biol 27:683–687

    Article  PubMed  CAS  Google Scholar 

  23. Wahl RL, Zasadny K, Helvie M, et al. (1993) Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 11:2101–2111

    PubMed  CAS  Google Scholar 

  24. Harris NL, Jaffe ES, Diebold J, et al. (2000) Lymphoma classification — from controversy to consensus: The R.E.A.L. and WHO Classification of lymphoid neoplasms. Ann Oncol 11(Suppl 1):3–10

    Article  PubMed  Google Scholar 

  25. Harris NL, Jaffe ES, Diebold J, et al. (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November 1997. J Clin Oncol 17:3835–3849

    PubMed  CAS  Google Scholar 

  26. Cheson BD, Pfistner B, Juweid ME, et al. (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579–586

    Article  PubMed  Google Scholar 

  27. Mikhaeel NG, Timothy AR, Hain SF, et al. (2000) 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas. Ann Oncol 11(Suppl 1):147–150

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Osaka University Graduate School of Medicine, 2-2-D9 Yamadaoka, Suita, Osaka, 565-0871, Japan

    Mitsuaki Tatsumi, Ichiro Higuchi & Jun Hatazawa

  2. Department of Radiology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan

    Mitsuaki Tatsumi & Hironobu Nakamura

  3. Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan

    Hiroyuki Sugahara & Yuzuru Kanakura

  4. Department of Surgery and Clinical Oncology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan

    Ichiro Higuchi & Hiroki Fukunaga

Authors
  1. Mitsuaki Tatsumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiroyuki Sugahara
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ichiro Higuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hiroki Fukunaga
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hironobu Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yuzuru Kanakura
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jun Hatazawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mitsuaki Tatsumi.

About this article

Cite this article

Tatsumi, M., Sugahara, H., Higuchi, I. et al. Standardized uptake value on FDG-PET as a marker for disease activity in patients with non-Hodgkin’s lymphoma: comparison with serum soluble interleukin-2 receptor values. Int J Clin Oncol 14, 150–158 (2009). https://doi.org/10.1007/s10147-008-0823-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-008-0823-x

Key words

Search

Navigation